Hospital Pharmacies to Procure 43% Market Share for Wilson’s Disease Diagnostics Market | FMI Study

During the forecast period 2023 to 2033, the Wilson’s Disease Diagnostics Market Demand is expected to grow at a value of 3.9% CAGR, according to Future Market Insights. By the year 2033, the global market for Wilson’s Disease Diagnostics is expected to rise up to a market valuation of US$ 896 Million. The global market for Wilson’s Disease Diagnostics is expected to experience significant growth in the coming years, driven by a number of factors including increasing awareness of the disease, growing demand for genetic testing, and the development of new diagnostic tools.

Wilson’s disease is a rare inherited disorder that affects the body’s ability to metabolize copper. The diagnosis of Wilson’s disease typically involves a combination of clinical evaluations, laboratory tests, and genetic testing. The initial step in diagnosing Wilson’s disease is often a thorough medical history and physical examination. The doctor will look for signs and symptoms such as liver abnormalities, neurological problems, and Kayser-Fleischer rings, which are copper deposits in the cornea of the eye. These findings, along with a family history of Wilson’s disease, can raise suspicion and prompt further testing.

Unlock growth potential with industry expertise. Download your market sample report now: https://www.futuremarketinsights.com/reports/sample/rep-gb-16763

Laboratory tests play a crucial role in diagnosing Wilson’s disease. The most common test is a blood test that measures the level of ceruloplasmin, a protein that carries copper in the blood. Low levels of ceruloplasmin may indicate Wilson’s disease. However, it is important to note that ceruloplasmin levels can also be low in other conditions, so further testing is necessary for a definitive diagnosis. Another important laboratory test is a 24-hour urine collection to measure the amount of copper excreted in the urine. Elevated copper levels in the urine are indicative of Wilson’s disease.

Genetic testing is often the final step in confirming a diagnosis of Wilson’s disease. This involves analyzing the ATP7B gene, which is responsible for producing a protein that helps transport copper out of the liver. Mutations in the ATP7B gene can disrupt copper metabolism, leading to the accumulation of copper in the body. Genetic testing can identify specific mutations in the ATP7B gene and help determine if a person has Wilson’s disease. It is particularly useful in cases where the clinical and laboratory findings are inconclusive or when there is a family history of the disease.

Key Takeaways from the Market Study

• The Wilson’s Disease Diagnostics market is expected to grow at a value of 3.9% CAGR in the forecast period 2023 to 2033
• By distribution channel, hospital pharmacies are expected to hold 43% of the market share in 2023 for Wilson’s Disease Diagnostics market.
• North America is expected to possess 46% market share for Wilson’s Disease Diagnostics market in 2023.
• Europe Wilson’s Disease Diagnostics market size is expected to possess 37% market share in 2023.

“With continued investment in research and development, it is likely that new diagnostic tools and techniques will be developed, leading to improved outcomes and quality of life for patients with Wilson’s disease.” states an FMI analyst

Wilson’s Disease Diagnostics Market Report Available at a Discount: https://www.futuremarketinsights.com/request-discount/rep-gb-16763

Competitive Landscape

Key players in the Wilson’s diseases diagnostics market are Orphalan, AstraZeneca, Vivet Therapeutics, Pfizer, Ultragenyx Pharmaceutical, Valeant Pharmaceuticals International, Inc., Noblepharma Co., Ltd., Merck & Co., Inc., Teva Pharmaceuticals, Wilson Therapeutics AB

• Ultragenyx Pharmaceutical is a biopharmaceutical company that has been involved in the development of a diagnostic test for Wilson’s disease called WDx. The WDx test is a blood test that measures the levels of ceruloplasmin, a protein that binds to copper in the blood. Low levels of ceruloplasmin are a characteristic feature of Wilson’s disease, and the WDx test can aid in the diagnosis of the condition.
• In 2018, Wilson Therapeutics AB was acquired by Alexion Pharmaceuticals, a biopharmaceutical company focused on the development of treatments for rare diseases. Following the acquisition, Alexion continued the development of WTX101 and submitted the drug for regulatory approval in the United States and Europe. In 2018, the US FDA granted WTX101 Breakthrough Therapy designation for the treatment of Wilson’s disease.

More Valuable Insights

Future Market Insights, in its new offering, presents an unbiased analysis of the global Wilson’s Disease Diagnostics market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

Customize Your Report Now: https://www.futuremarketinsights.com/customization-available/rep-gb-16763

Key Segments Profiled in the Wilson’s Disease Diagnostics Industry Survey

Drug Class:

• Penicillamine
• Trientine
• Tetrathiomolybdate

Route of Administration:

• Oral
• Parenteral

Distribution Channel:

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

About Future Market Insights, Inc.

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs